Pharma Majors Face 'Patent Cliff'

Multinational pharmaceutical companies face significant declines in revenue when the patents on their best-selling drugs expire, allowing for the diffusion of cheaper copies. BMI identifies two companies as particularly vulnerable to generic competition in 2014; Teva Pharmaceuticals based in Israel and Britain's AstraZeneca Plc. We look at what generic competition means for these two firms as well as for the industry as a whole. This podcast features Pharmaceutical & Healthcare analyst Asif Ashraf.

This blog is tagged to:
Sector: Pharmaceuticals & Healthcare
Geography: India, United Kingdom, Global, Israel
Tags: Generic Pharmaceuticals, Pharmaceuticals, Teva, AstraZeneca, Patented Medicines, Asif Ashraf

Access all of our latest analysis, data and forecasts - request a trial